A phase 2 trial of Coversin in the inflammatory-mediated eye disorder Atopic Keratoconjunctivitis (AKC).
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Coversin (Primary)
- Indications Keratoconjunctivitis
- Focus Therapeutic Use
- 09 Feb 2018 New trial record
- 06 Feb 2018 According to an Akari Therapeutics media release, the company expects to commence this study in first half of 2018.